**Name of Journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 64250

**Manuscript Type:** MINIREVIEWS

**Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma**

Dai K *et al*. CAR-NK cells targeting hepatocellular carcinoma

Kai Dai, Yin Wu, Sha She, Qian Zhang

**Kai Dai, Yin Wu, Sha She, Qian Zhang,** Department of Infectious Diseases, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei Province, China

**Author contributions:** Dai K performed the majority of the writing and prepared the table; Wu Y, She S and Zhang Q carried out the literature review for data collection, and coordinated the writing of the paper; all authors have read and approve the final manuscript.

**Supported by** The National Natural Science Foundation of China, No. 81972673.

**Corresponding author: Kai Dai, MD, PhD, Doctor,** Department of Infectious Diseases, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuchang District, Wuhan 430060, Hubei Province, China. daikai@whu.edu.cn

**Received:** February 20, 2021

**Revised:** August 4, 2021

**Accepted:** October 27, 2021

**Published online:** December 15, 2021

**Abstract**

With the advance of genome engineering technology, chimeric antigen receptors (CARs)-based immunotherapy has become an emerging therapeutic strategy for tumors. Although initially designed for T cells in tumor immunotherapy, CARs have been exploited to modify the function of natural killer (NK) cells against a variety of tumors, including hepatocellular carcinoma (HCC). CAR-NK cells have the potential to sufficiently kill tumor antigen-expressing HCC cells, independent of major histocompatibility complex matching or prior priming. In this review, we summarize the recent advances in genetic engineering of CAR-NK cells against HCC and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against HCC.

**Key Words:** Chimeric antigen receptors; Natural killer cells; Hepatocellular carcinoma; Immunotherapy; Genome engineering

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Dai K, Wu Y, She S, Zhang Q. Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma. *World J Gastrointest Oncol* 2021; 13(12): 2029-2037

**URL:** https://www.wjgnet.com/1948-5204/full/v13/i12/2029.htm

**DOI:** https://dx.doi.org/10.4251/wjgo.v13.i12.2029

**Core Tip:** Chimeric antigen receptors (CARs)-based immunotherapy is an emerging therapeutic strategy for tumors. This review summarizes the recent advances in genetic engineering of CAR-natural killer (NK) cells against hepatocellular carcinoma and discuss the current challenges and prospects of CAR-NK cells as a revolutionary cellular immunotherapy against hepatocellular carcinoma.

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is the predominant form of primary liver cancer, the sixth most commonly diagnosed cancer, and the third leading cause of cancer death worldwide[1,2]. The key risk factors of HCC include infection with hepatitis B virus or hepatitis C virus, alcohol consumption, non-alcoholic fatty liver disease, and aflatoxin exposure[3]. Surgery is the prevalent treatment for HCC. However, recurrence of HCC severely decreases the survival rate.

Locoregional therapies, including percutaneous ablation and intra-arterial chemotherapy, are alternative treatment approaches and rely on the grade of HCC. Unfortunately, more than 70% of patients with advanced HCC have little chance for transplant, surgery, or locoregional therapy. In the recent decade, cancer immunotherapy has become a novel emerging therapeutic strategy, improving treatment effect *via* mobilizing patients’ immune systems to launch efficient anti-tumor reactions against cancer progression. Adoptive transfer of immune cells, as an immunotherapeutic approach, is expected to improve HCC prognosis by passively infusing autologous or allogenic leukocytes after *ex vivo* expansion and activation. Natural killer (NK) cells are a persistent research focus in the field of immunotherapy, due to their significant anti-tumor activity.

**NK CELL BIOLOGY**

NK cells, which make up 5%-15% of human blood leukocytes and 50% of hepatic innate immune cells, are the major innate lymphocytes executing anti-tumor and anti-viral immunity[4]. Based on the expression of cluster of differentiation (CD)16 and CD56, human NK cells can be divided into two subpopulations. The majority (85%-95%) of the peripheral blood NK cells are CD56dimCD16high, showing a developmentally mature phenotype, and mediate high cytotoxicity upon encountering target cells. The remaining minority of NK cells are the CD56brightCD16low/− subset, which have an immature phenotype and lower cytotoxicity upon activation[5].

Unlike T cells, the cytotoxicity of NK cells does not rely on T cell receptor (TCR)-mediated specific antigen recognition and is thus independent of major histocompatibility complex (MHC) expression. Instead, NK cell activity is regulated by a wide spectrum of activating and inhibitory receptors (Table 1) that induce positive and negative signals to comprehensively control NK cell behavior upon contacting target cells[6]. In this regard, tumor cells that downregulate MHC expression are sensitive to NK cell cytotoxicity, owing to weaker killer cell immunoglobulin-like receptor (commonly known as KIR)-mediated inhibitory signals. Similar to cytotoxic T cells, activated NK cells express and release lytic molecules, such as perforin and granzyme B, to kill tumor cells. Additionally, NK cells secrete an array of cytokines, including interferon-g, tumor necrosis factor (TNF), and granulocyte-macrophage colony-stimulating factor, to induce the activation of T cells and innate immune cells (dendritic cells, macrophages, and neutrophils), and result in the promotion of immunity against malignant cells and the tumorigenic microenvironment[4].

**CARS FOR TUMOR TREATMENT**

Thanks to genome editing technology, CARs were initially designed for T cell-mediated immunotherapy against relapsed or refractory B-cell malignancies[7]. A CAR is an antibody-derived antigen-recognizing domain, linked with T cell signaling domains. When expressed by a T cell, the CAR targets a specific antigen and transduces activating signals to that T cell. A CAR consists of three domains, namely an ectodomain, a transmembrane domain, and an intracellular signaling domain[8]. The ectodomain is a single-chain variable fragment (scFv) comprising the variable regions of heavy and light chains of an antibody connected with a short linker peptide of 10-25 amino acids. The intracellular domain is conventionally derived from the TCR CD3ζ chain and/or other key accessory proteins for relaying activating signals. Three generations of CARs have been developed to date. The first-generation CARs contain CD3ζ alone. The second-generation CARs integrate an extra costimulatory domain from CD28 or 4-1BB. The third-generation CARs contain more than one costimulatory domain[9].The latest ¾ fourth-generation ¾ CARs possess supplementary exogenous proteins, such as cytokines, to enhance the lifespan and effector function of NK cells[10].

Although T cells armed with CARs (hereinafter referred to as “CAR-T cells”) have demonstrated unprecedented efficacy in boosting anti-tumor immunity, but they have intrinsic shortcomings[11,12]. First, CAR-T cells require prior antigen priming, which depends on the expression of MHC molecules on target cells. However, various types of tumor cells downregulate MHC expression and therefore escape from the attack of CAR-T cells. Second, before infusion of CAR-T cells, patients have to receive lymphodepleting treatment to facilitate the *in vivo* persistence of the CAR-T cells. However, a large number of CAR-T cells in the recipient increases the risk of graft *vs* host disease (commonly known as GVHD). Third, activated CAR-T cells produce enormous amounts of cytokines, including interleukin (IL)-1a, IL-2, IL-6, TNF-α, MCP-1, IL-8, IL-10 and IL-15, rendering the cytokine release syndrome (otherwise known as CRS) and neurotoxicity. Compared to T cells, NK cells overcome these disadvantages because they function in an MHC-independent manner, without triggering GVHD, and produce a distinct spectrum of cytokines.

**CAR-NK CELLS**

***CAR constructs for NK cells***

For NK cells, the CAR structure is quite similar to that of T cells. The extracellular scFv is also derived from an antibody against a tumor antigen. So far, the tumor antigens targeted by engineered scFv involve CD19 and CD20 (B-cell acute and chronic leukemia antigen)[13], human epidermal growth factor receptor 2 (commonly known as HER2; breast cancer)[14], GD2 (neuroblastoma and melanoma)[15], CD138 (multiple myeloma)[16], CD4 (T cell lymphoma)[17], and epidermal growth factor receptor (EGFR) which is overexpressed in multiple tumors[18]. Some researchers have designed CAR-NK cells targeting certain immunosuppressive cells, such as alternatively-activated macrophages and myeloid-derived suppressor cells, to enhance anti-tumor immunity[19,20]. Moreover, a recent endeavor has been made to create a bispecific CAR featuring an scFv that targets two antigens simultaneously. NK cells equipped with this bispecific CAR are supposed to execute cytotoxicity more efficiently, in case one antigen is weakly expressed or absent on certain tumor cells[21].

The transmembrane domain of a CAR belongs to CD8a, CD28, CD3, or ICOS, with some exceptions derived from NKG2D[22]. Recent findings suggest that the sequences and locations of the transmembrane domain should be delicately designed to achieve the best function[23]. The intracellular domain is key to the signal transduction activity and consequent NK cell activation upon the engagement of the scFv with tumor antigens. Most CAR-NK cells exploit CD3ζ as a signaling domain to transduce activating signals because the immunoreceptor tyrosine-based activation motif (also known as ITAM) of CD3ζ initiates NK cell killing[24-26]. Additional costimulatory domains derived from CD28, CD137 (4-1BB), or CD244 (2B4) are usually required for efficient killing[22,27]. In recent research, replacing CD3ζ with the intracellular region of DAP12 has resulted in a better effect on glioblastoma[28]. The most common CAR constructs used in CAR-NK cells have been summarized elsewhere[8].

***Sources of CAR-NK cells***

Currently, clinical-grade NK cells are manufactured on a large scale from the following sources.

**NK92 cell line:** The NK-92 cell line was established from a patient with large granular lymphoma in 1994. It does not attack recipients’ allogeneic cells but kills a wide range of tumor cells, such as leukemia and melanoma. The cell line is easy to grow *in vitro*, making it an attractive agent for adoptive cancer immunotherapy. However, its tumorigenicity potential, deficiency in CD16 and NKp44 expression, and the requirement for lethal irradiation before adoptive transfer pose concerns about clinical safety and therapeutic efficiency[29].

**Peripheral blood mononuclear cells (PBMCs):** Sufficient allogeneic NK cells can be enriched from PBMCs of a patient or healthy donor, followed by *ex vivo* stimulation, expansion, and genetic engineering. PBMC-derived CAR-NK cells are predominantly CD56dimCD16+ mature NK cells with high cytotoxicity, making them especially suitable for either autologous or allogeneic transfer[8].

**Umbilical cord blood (UBC):** As an alternative NK cell source, UBC with identified MHC types can be obtained from UBC banks. Nonetheless, the NK cell abundance in UBC is relatively low, so it takes a long *ex vivo* expansion and activation procedure before sufficient NK cells are generated. Another issue involves UBC-derived NK cells exhibiting an immature phenotype and being less cytotoxic to target cells[30].

**Hematopoietic progenitor cells (commonly known as HPCs):** CD34+ HPCs are sorted from bone marrow, embryonic stem cells, mobilized peripheral blood, or UBC. They are expanded and differentiated into NK cells *ex vivo*, under the effect of a set of cytokines. HPC-derived NK cells are mature and significantly cytotoxic to leukemia cells[31].

**Induced pluripotent stem cells (iPSCs):** iPSCs are derived from mature somatic cells that have been reprogrammed back into a pluripotent stem cell state. They enable the development of an unlimited source of multiple cell types needed for therapeutic purposes. Theoretically, one iPSC is competent to generate a large quantity of homogeneous CAR-NK cells. However, iPSC-derived NK cells are relatively immature and less cytotoxic, posing the challenge of inducing both phenotypically and functionally mature NK cells[8]. A recent study developed a robust and efficient manufacturing system for the differentiation and expansion of high-quality iPSC-derived NK cells that produced inflammatory cytokines and exerted strong cytotoxicity against an array of hematologic and solid tumors[32].

**CAR-NK CELLS IN HCC THERAPY**

Both academia and industry have made rapid progress in developing CAR-engineered immune cells for HCC[33,34]. One of the major challenges for CAR-based immunotherapy for HCC is to target a specific, safe, and effective tumor antigen. Currently, the following tumor antigens are considered candidate targets of CAR-based immunotherapy for HCC: glypican-3 (GPC3), α-fetoprotein, epithelial cell adhesion molecule (commonly known as EpCAM), and mucin-1 (commonly known as MUC1)[35,36]. Of note, glypican-3 is a glycoprotein overexpressed on the cell surface of HCC tissues but not in healthy liver[37]. A bispecific CAR targeting GPC3 and the asialoglycoprotein receptor 1 (commonly known as ASGR1) and featuring CD3ζ and 28BB (containing CD28 and 4-1BB signaling domains) has been tested in an HCC xenograft mouse model[38].

Although CAR-NK cells have been tested in a few clinical trials against leukemia, lymphoma, and several solid tumors, to our knowledge, no clinical trials have been performed to evaluate the efficacy of CAR-NK cells in HCC treatment. Several laboratory studies of CAR-NK cells against HCC have been conducted and showed the bright prospect of CAR-NK-based HCC immunotherapy.

The first report of CAR-NK cells against HCC was published in 2018. Yu *et al*[39] developed GPC3-CAR-NK-92 cells and demonstrated the potent anti-tumor properties of these cells. The CAR construct comprised a CD8α signal peptide, a humanized GPC3-specific scFv (known as “hu9F2”), a CD8α hinge region, and a CD28 transmembrane region followed by the intracellular domains of CD28 and CD3ζ. The GPC3-CAR-NK-92 cells showed potent cytotoxicity and cytokine production upon encountering HCC cells with either high or low GPC3 expression, both *in vitro* and *in vivo*. Notably, the GPC3-CAR-NK-92 cells were cytotoxic to GFP3-negative HCC cells. Huang *et al*[40] made a further modification to GPC3-CAR-NK-92 cells by replacing the intracellular domains of CD28 and CD3ζ with the costimulatory domains of DNAM1 and 2B4. DNAM1, also known as CD226, is a costimulatory receptor in cytotoxic T cells, NK cells, and monocytes[41]. DNAM1 cross-linking results in phosphorylation of its cytoplasmic tyrosine residues and drives NK cell cytotoxicity[42]. 2B4, as above-mentioned, is known as CD244 and harbors a cytoplasmic domain containing immunoreceptor tyrosine-based switch motifs (commonly known as ITSMs) that are responsible for interacting with multiple signaling adaptors and transmitting activating signals[43]. This modification endowed GPC3-CAR-NK-92 cells with faster expansion, lower apoptosis and higher cytotoxic abilities than their original counterparts[40].

Tseng *et al*[44] reported that NK cells transduced with a CAR that targets CD147, a cell surface marker that is significantly upregulated in HCC, can effectively kill various malignant HCC cell lines *in vitr*o, as well as HCC tumors in xenograft and patient-derived xenograft mouse models. In this study, the CD147-CAR contained the scFv of the anti-CD147 antibody derived from clone 5F6 with optimization, a human IgG1-CH2CH3 spacer, a transmembrane domain of CD28, the intracellular domain of CD28-4-1BB, and intracellular signaling domains of the TCR-ζ chain. The CAR-encoding retrovirus was transduced into the NK-92MI cell line, which is an IL-2-dependent NK cell line derived from PBMCs obtained from a patient with rapidly progressive non-Hodgkin's lymphoma. These CD147-CAR-NK-92MI cells were effectively activated by CD147+ HCC cell lines and demonstrated impressive cytotoxicity against the target HCC cell lines. When using primary PBMC-derived NK cells to prepare CD147-CAR-NK cells, the researchers observed efficient killing effects on susceptible target cells, including SKHep1, Huh7, and HepG2, *etc*. Furthermore, primary NK cells isolated from different zones of HCC liver tissue and engineered to express CD147-CAR can kill CD147+ HCC cell lines selectively and specifically. This study offers a valuable insight into manufacturing CD147-CAR-NK cells as either an autologous or an allogeneic off-the-shelf cell-based product.

Bouattour *et al*[45] developed c-MET-CAR-NK cells and tested the efficacy against HCC cell lines. c-MET is the product of the proto-oncogene *MET* and actsas a tumorigen in HCC, since enhanced c-MET activity initiates and contributes to the progression of HCC. The CAR construct contained an scFv of an anti-c-MET antibody fused with truncated human EGFR (referred to as huEGFRt). The intracellular domain of the CAR comprised the 4-1BB and the DAP12 cytoplasmic domain. c-MET-CAR-encoding lentivirus was then prepared and transduced into human PBMC-derived NK cells. The resultant c-MET-CAR-NK cells remarkably killed HepG2 cells *in vitro*; however, no data were generated to demonstrate the effect of c-MET-CAR-NK cells *in vivo*. Of note, c-MET-CAR-NK cells could be potentially used to treat other solid tumors, because the upregulation of c-MET has been found in breast cancer, lung cancer, and colorectal cancer[46-48].

**CHALLENGES TO BE ADDRESSED**

Although CAR-NK cells have demonstrated their potency and advantages in tumor killing, technical or clinical issues remain to be addressed that will optimize CAR-NK-based immunotherapy against HCC.

First and foremost, stringent screening of HCC-specific antigens is necessary to minimize or avoid severe adverse effects due to on-target/off-tumor toxicity. On-target/off-tumor toxicity arises from the simultaneous expression of a target antigen on both tumor and healthy tissues[49]. This toxicity, sometimes lethal, can be reduced by careful design of CAR constructs that improve the recognition of tumor cells. One such approach is to affinity-tune CARs so that they detect tumor cells with a high density of surface antigens and do not react against normal cells that have low antigen densities[50]. Altering the scFv binding domain *via* mutagenesis or recombination of heavy and light chains can genetically tune the affinity of a CAR to fulfill this purpose[51,52]. The intracellular signaling domain of a CAR can also be tuned to induce a moderate activating signal to weaken CAR-mediated direct cytotoxicity.

Another issue is the promotion of CAR-NK cell expansion and persistence *in vivo*. Insufficient *in vivo* expansion of CAR-NK cells after adoptive transfer owing to unidentified factors is a particularly serious challenge. A recent clinical trial has demonstrated that incorporating IL-15 into CAR-NK cells remarkably augmented *in vivo* expansion[53].

The third issue involves the effect of CAR-NK cells on solid tumors like HCC, which remains unsatisfactory. The heterogeneity of solid tumors, the harsh tumor microenvironment that induces NK cell exhaustion, the limited infiltration from the bloodstream into tumor sites, and the immunosuppression caused by immunosuppressive cells and metabolic disturbances comprehensively inhibit CAR-NK cell function[54]. More efforts have to be made to deal with these challenges, one-by-one, to build more efficient CAR-NK cells against HCC and other solid tumors. With the advance of genetic engineering science, CAR-NK cells equipped with genetically-incorporated cytokines, antibodies, survival factors, constitutively-active signaling molecules, *etc*. will greatly promote NK cell proliferation, persistence, migration, and penetration into HCC.

**CONCLUSION**

CAR-NK cell therapy is an emerging immunotherapy against tumors, including HCC. Its advantage in manufacturing off-the-shelf cellular therapy products with high clinical availability and safety makes it a promising anti-HCC approach. Recent breakthroughs in genome editing techniques have potentiated the production of novel CAR-NK cells with high anti-HCC specificity and activity and low on-target/off-tumor toxicity. Innovative engineering tools including CRISPR-Cas9, zinc finger nucleases (referred to as ZFNs), transcription activator-like effector nucleases (referred to as TALENs), and meganucleases are expected to revolutionize the design and creation of CAR constructs for NK cells in the future. With the great efforts being made to enhance safety and activity through laboratory studies and clinical trials, we are confident in the eventual overcoming of the remaining challenges to CAR-NK cell therapy, bringing hope to HCC patients and their families.

**REFERENCES**

1 **Johnston MP**, Khakoo SI. Immunotherapy for hepatocellular carcinoma: Current and future. *World J Gastroenterol* 2019; **25**: 2977-2989 [PMID: 31293335 DOI: 10.3748/wjg.v25.i24.2977]

2 **Sung H**, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021; **71**: 209-249 [PMID: 33538338 DOI: 10.3322/caac.21660]

3 **Janevska D**, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. *Open Access Maced J Med Sci* 2015; **3**: 732-736 [PMID: 27275318 DOI: 10.3889/oamjms.2015.111]

4 **Shimasaki N**, Jain A, Campana D. NK cells for cancer immunotherapy. *Nat Rev Drug Discov* 2020; **19**: 200-218 [PMID: 31907401 DOI: 10.1038/s41573-019-0052-1]

5 **Stabile H**, Fionda C, Gismondi A, Santoni A. Role of Distinct Natural Killer Cell Subsets in Anticancer Response. *Front Immunol* 2017; **8**: 293 [PMID: 28360915 DOI: 10.3389/fimmu.2017.00293]

6 **Basar R**, Daher M, Rezvani K. Next-generation cell therapies: the emerging role of CAR-NK cells. *Blood Adv* 2020; **4**: 5868-5876 [PMID: 33232480 DOI: 10.1182/bloodadvances.2020002547]

7 **Halim L**, Maher J. CAR T-cell immunotherapy of B-cell malignancy: the story so far. *Ther Adv Vaccines Immunother* 2020; **8**: 2515135520927164 [PMID: 32524070 DOI: 10.1177/2515135520927164]

8 **Xie G**, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: A promising cellular immunotherapy for cancer. *EBioMedicine* 2020; **59**: 102975 [PMID: 32853984 DOI: 10.1016/j.ebiom.2020.102975]

9 **June CH**, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. *Science* 2018; **359**: 1361-1365 [PMID: 29567707 DOI: 10.1126/science.aar6711]

10 **Tokarew N**, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. *Br J Cancer* 2019; **120**: 26-37 [PMID: 30413825 DOI: 10.1038/s41416-018-0325-1]

11 **Stoiber S**, Cadilha BL, Benmebarek MR, Lesch S, Endres S, Kobold S. Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy. *Cells* 2019; **8** [PMID: 31108883 DOI: 10.3390/cells8050472]

12 **Brudno JN**, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. *Blood Rev* 2019; **34**: 45-55 [PMID: 30528964 DOI: 10.1016/j.blre.2018.11.002]

13 **Boissel L**, Betancur-Boissel M, Lu W, Krause DS, Van Etten RA, Wels WS, Klingemann H. Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity. *Oncoimmunology* 2013; **2**: e26527 [PMID: 24404423 DOI: 10.4161/onci.26527]

14 **Zhang C**, Burger MC, Jennewein L, Genßler S, Schönfeld K, Zeiner P, Hattingen E, Harter PN, Mittelbronn M, Tonn T, Steinbach JP, Wels WS. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. *J Natl Cancer Inst* 2016; **108** [PMID: 26640245 DOI: 10.1093/jnci/djv375]

15 **Esser R**, Müller T, Stefes D, Kloess S, Seidel D, Gillies SD, Aperlo-Iffland C, Huston JS, Uherek C, Schönfeld K, Tonn T, Huebener N, Lode HN, Koehl U, Wels WS. NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin. *J Cell Mol Med* 2012; **16**: 569-581 [PMID: 21595822 DOI: 10.1111/j.1582-4934.2011.01343.x]

16 **Jiang H**, Zhang W, Shang P, Zhang H, Fu W, Ye F, Zeng T, Huang H, Zhang X, Sun W, Man-Yuen Sze D, Yi Q, Hou J. Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells. *Mol Oncol* 2014; **8**: 297-310 [PMID: 24388357 DOI: 10.1016/j.molonc.2013.12.001]

17 **Pinz KG**, Yakaboski E, Jares A, Liu H, Firor AE, Chen KH, Wada M, Salman H, Tse W, Hagag N, Lan F, Leung EL, Jiang X, Ma Y. Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells. *Oncotarget* 2017; **8**: 112783-112796 [PMID: 29348865 DOI: 10.18632/oncotarget.22626]

18 **Li Y**, Hermanson DL, Moriarity BS, Kaufman DS. Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity. *Cell Stem Cell* 2018; **23**: 181-192.e5 [PMID: 30082067 DOI: 10.1016/j.stem.2018.06.002]

19 **Zhang P**, Zhao S, Wu C, Li J, Li Z, Wen C, Hu S, An G, Meng H, Zhang X, Yang L. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. *Immunotherapy* 2018; **10**: 935-949 [PMID: 30149762 DOI: 10.2217/imt-2018-0012]

20 **Parihar R**, Rivas C, Huynh M, Omer B, Lapteva N, Metelitsa LS, Gottschalk SM, Rooney CM. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors. *Cancer Immunol Res* 2019; **7**: 363-375 [PMID: 30651290 DOI: 10.1158/2326-6066.CIR-18-0572]

21 **Klapdor R**, Wang S, Morgan M, Dörk T, Hacker U, Hillemanns P, Büning H, Schambach A. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer. *Int J Mol Sci* 2019; **20** [PMID: 30717444 DOI: 10.3390/ijms20030660]

22 **Zhao Y**, Zhou X. Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy. *Immunotherapy* 2020; **12**: 653-664 [PMID: 32436428 DOI: 10.2217/imt-2019-0139]

23 **Guedan S**, Posey AD Jr, Shaw C, Wing A, Da T, Patel PR, McGettigan SE, Casado-Medrano V, Kawalekar OU, Uribe-Herranz M, Song D, Melenhorst JJ, Lacey SF, Scholler J, Keith B, Young RM, June CH. Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. *JCI Insight* 2018; **3** [PMID: 29321369 DOI: 10.1172/jci.insight.96976]

24 **Lanier LL**. Up on the tightrope: natural killer cell activation and inhibition. *Nat Immunol* 2008; **9**: 495-502 [PMID: 18425106 DOI: 10.1038/ni1581]

25 **Tassi I**, Klesney-Tait J, Colonna M. Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. *Immunol Rev* 2006; **214**: 92-105 [PMID: 17100878 DOI: 10.1111/j.1600-065X.2006.00463.x]

26 **Vivier E**, Nunès JA, Vély F. Natural killer cell signaling pathways. *Science* 2004; **306**: 1517-1519 [PMID: 15567854 DOI: 10.1126/science.1103478]

27 **Hermanson DL**, Kaufman DS. Utilizing chimeric antigen receptors to direct natural killer cell activity. *Front Immunol* 2015; **6**: 195 [PMID: 25972867 DOI: 10.3389/fimmu.2015.00195]

28 **Müller N**, Michen S, Tietze S, Töpfer K, Schulte A, Lamszus K, Schmitz M, Schackert G, Pastan I, Temme A. Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. *J Immunother* 2015; **38**: 197-210 [PMID: 25962108 DOI: 10.1097/CJI.0000000000000082]

29 **Zhang J**, Sun R, Wei H, Zhang J, Tian Z. Characterization of interleukin-15 gene-modified human natural killer cells: implications for adoptive cellular immunotherapy. *Haematologica* 2004; **89**: 338-347 [PMID: 15020274]

30 **Sarvaria A**, Jawdat D, Madrigal JA, Saudemont A. Umbilical Cord Blood Natural Killer Cells, Their Characteristics, and Potential Clinical Applications. *Front Immunol* 2017; **8**: 329 [PMID: 28386260 DOI: 10.3389/fimmu.2017.00329]

31 **Luevano M**, Madrigal A, Saudemont A. Generation of natural killer cells from hematopoietic stem cells *in vitro* for immunotherapy. *Cell Mol Immunol* 2012; **9**: 310-320 [PMID: 22705914 DOI: 10.1038/cmi.2012.17]

32 **Cichocki F**, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, Wang H, Tuininga K, Felices M, Davis ZB, Bendzick L, Clarke R, Stokely L, Rogers P, Ge M, Robinson M, Rezner B, Robbins DL, Lee TT, Kaufman DS, Blazar BR, Valamehr B, Miller JS. iPSC-derived NK cells maintain high cytotoxicity and enhance *in vivo* tumor control in concert with T cells and anti-PD-1 therapy. *Sci Transl Med* 2020; **12** [PMID: 33148626 DOI: 10.1126/scitranslmed.aaz5618]

33 **Harrer DC**, Dörrie J, Schaft N. Chimeric Antigen Receptors in Different Cell Types: New Vehicles Join the Race. *Hum Gene Ther* 2018; **29**: 547-558 [PMID: 29320890 DOI: 10.1089/hum.2017.236]

34 **Patel S**, Burga RA, Powell AB, Chorvinsky EA, Hoq N, McCormack SE, Van Pelt SN, Hanley PJ, Cruz CRY. Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer. *Front Oncol* 2019; **9**: 196 [PMID: 31024832 DOI: 10.3389/fonc.2019.00196]

35 **Guo J**, Tang Q. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. *Cancer Gene Ther* 2021 [PMID: 33500535 DOI: 10.1038/s41417-020-00259-4]

36 **Mizukoshi E**, Kaneko S. Immune cell therapy for hepatocellular carcinoma. *J Hematol Oncol* 2019; **12**: 52 [PMID: 31142330 DOI: 10.1186/s13045-019-0742-5]

37 **Guo M**, Zhang H, Zheng J, Liu Y. Glypican-3: A New Target for Diagnosis and Treatment of Hepatocellular Carcinoma. *J Cancer* 2020; **11**: 2008-2021 [PMID: 32127929 DOI: 10.7150/jca.39972]

38 **Chen C**, Li K, Jiang H, Song F, Gao H, Pan X, Shi B, Bi Y, Wang H, Wang H, Li Z. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma. *Cancer Immunol Immunother* 2017; **66**: 475-489 [PMID: 28035433 DOI: 10.1007/s00262-016-1949-8]

39 **Yu M**, Luo H, Fan M, Wu X, Shi B, Di S, Liu Y, Pan Z, Jiang H, Li Z. Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma. *Mol Ther* 2018; **26**: 366-378 [PMID: 29339014 DOI: 10.1016/j.ymthe.2017.12.012]

40 **Huang Y**, Zeng J, Liu T, Xu Q, Song X, Zeng J. DNAM1 and 2B4 Costimulatory Domains Enhance the Cytotoxicity of Anti-GPC3 Chimeric Antigen Receptor-Modified Natural Killer Cells Against Hepatocellular Cancer Cells in vitro. *Cancer Manag Res* 2020; **12**: 3247-3255 [PMID: 32440221 DOI: 10.2147/CMAR.S253565]

41 **Sanchez-Correa B**, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM, Arcos MJ, Bañas H, Casas-Avilés I, Durán E, Alonso C, Solana R, Tarazona R. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy. *Cancers (Basel)* 2019; **11** [PMID: 31234588 DOI: 10.3390/cancers11060877]

42 **Shibuya A**, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T, Kitamura T, Nicholl J, Sutherland GR, Lanier LL, Phillips JH. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. *Immunity* 1996; **4**: 573-581 [PMID: 8673704 DOI: 10.1016/s1074-7613(00)70060-4]

43 **Agresta L**, Hoebe KHN, Janssen EM. The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment. *Front Immunol* 2018; **9**: 2809 [PMID: 30546369 DOI: 10.3389/fimmu.2018.02809]

44 **Tseng HC**, Xiong W, Badeti S, Yang Y, Ma M, Liu T, Ramos CA, Dotti G, Fritzky L, Jiang JG, Yi Q, Guarrera J, Zong WX, Liu C, Liu D. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. *Nat Commun* 2020; **11**: 4810 [PMID: 32968061 DOI: 10.1038/s41467-020-18444-2]

45 **Bouattour M**, Raymond E, Qin S, Cheng AL, Stammberger U, Locatelli G, Faivre S. Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma. *Hepatology* 2018; **67**: 1132-1149 [PMID: 28862760 DOI: 10.1002/hep.29496]

46 **Yan S**, Jiao X, Zou H, Li K. Prognostic significance of c-Met in breast cancer: a meta-analysis of 6010 cases. *Diagn Pathol* 2015; **10**: 62 [PMID: 26047809 DOI: 10.1186/s13000-015-0296-y]

47 **Pyo JS**, Kang G, Cho WJ, Choi SB. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non-small cell lung cancers: A meta-analysis. *Pathol Res Pract* 2016; **212**: 710-716 [PMID: 27465837 DOI: 10.1016/j.prp.2016.05.006]

48 **Liu Y**, Yu XF, Zou J, Luo ZH. Prognostic value of c-Met in colorectal cancer: a meta-analysis. *World J Gastroenterol* 2015; **21**: 3706-3710 [PMID: 25834339 DOI: 10.3748/wjg.v21.i12.3706]

49 **Castellarin M**, Sands C, Da T, Scholler J, Graham K, Buza E, Fraietta JA, Zhao Y, June CH. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. *JCI Insight* 2020; **5** [PMID: 32544101 DOI: 10.1172/jci.insight.136012]

50 **Zhao Y**, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. *J Immunol* 2009; **183**: 5563-5574 [PMID: 19843940 DOI: 10.4049/jimmunol.0900447]

51 **Carter P**, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM. Humanization of an anti-p185HER2 antibody for human cancer therapy. *Proc Natl Acad Sci U S A* 1992; **89**: 4285-4289 [PMID: 1350088 DOI: 10.1073/pnas.89.10.4285]

52 **Drent E**, Themeli M, Poels R, de Jong-Korlaar R, Yuan H, de Bruijn J, Martens ACM, Zweegman S, van de Donk NWCJ, Groen RWJ, Lokhorst HM, Mutis T. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization. *Mol Ther* 2017; **25**: 1946-1958 [PMID: 28506593 DOI: 10.1016/j.ymthe.2017.04.024]

53 **Liu E**, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. *N Engl J Med* 2020; **382**: 545-553 [PMID: 32023374 DOI: 10.1056/NEJMoa1910607]

54 **Yilmaz A**, Cui H, Caligiuri MA, Yu J. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. *J Hematol Oncol* 2020; **13**: 168 [PMID: 33287875 DOI: 10.1186/s13045-020-00998-9]

**Footnotes**

**Conflict-of-interest statement:** The authors declare no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:**Invited article; Externally peer reviewed.

**Peer-review started:** February 20, 2021

**First decision:** July 29, 2021

**Article in press:** October 27, 2021

**Specialty type:** Oncology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Inmutto N, Trotovšek B **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Table 1 Activating and inhibitory receptors on human natural killer cells**

|  |  |  |
| --- | --- | --- |
|  | **Receptor** | **Ligand** |
| Activating receptors | CD16 | Fc region of IgG |
|  | NKG2D | MICA/B, ULBP1-6 |
|  | NKp30 (CD337) | B7-H6, BAT3, HCMV pp65 |
|  | NKp44 (CD336) | Viral HA and HN, PCNA, MLL5, PDGF-DD |
|  | NKp46 (CD335) | Viral HA and HN, CFP |
|  | NKp65 | KACL |
|  | NKp80 | AICL1 |
|  | CD94-NKG2C/E/H | HLA-E (for CD94-NKG2C) |
|  | 2B4 (CD244) | CD48 |
|  | DNAM-1 (CD226) | PVR (Necl5, CD155), nectin 2 (CD112) |
|  | Activating KIRs | HLA-A11, -Bw4 |
|  | CRTAM (CD355) | Necl-2 |
|  | Tactile (CD96) | CD155 |
| Inhibitory receptors | Inhibitory KIRs | HLA class I |
|  | CD94-NKG2A/B | HLA-E |
|  | NKR-P1A | LLT1 |
|  | TIGIT | PVR (Necl5, CD155), nectin 2 (CD112) |
|  | LIR-1 (ILT-2/CD85j/LILRB1) | HLA (α3), HCMV UL18 |
|  | IRp60 (CD300a) | PS, PE |
|  | CEACAM1 (CD66) | CEACAM1 (CD66), TIM-3 (HAVCR2) |

AICL: Activation-induced C-type lectin; BAT3: Human leukocyte antigen-B-associated transcript 3; CEACAM: Carcinoembryonic antigen-related cell adhesion molecules; CFP: Complement factor P; CRTAM: Class I-restricted T cell-associated molecule; DNAM-1: DNAX accessory molecule 1; H60: Minor histocompatibility protein 60; HA: Hemagglutinin; HAVCR2: Hepatitis A virus cellular receptor 2; HCMV: Human cytomegalovirus; HN: Hemagglutinin-neuraminidase; IgG: Immunoglobulin G; ILT-2: Immunoglobulin-like transcript 2; IRp60: Inhibitory receptor protein 60; KACL: Keratinocyte-associated C-type lectin; KIR: Killer-cell immunoglobulin-like receptor; LILRB1: Leukocyte immunoglobulin-like receptor, subfamily B member 1; LIR-1: Leukocyte immunoglobulin-like receptor 1; LLT1: Lectin-like transcript 1; MHC: Major histocompatibility complex; MIC: MHC class I chain-related protein; MLL5: Mixed lineage leukemia 5; MULT-1: Mouse UL-16- binding protein-like transcript 1; Necl: Nectin-like molecules; PCNA: Proliferating cell nuclear antigen; PDGF: Platelet-derived growth factor; PE: Phosphatidylethanolamine; PILR: Paired immunoglobulin-like type 2 receptor; PS: Phosphatidylserine; PVR: Poliovirus receptor; Rae-1: Retinoic acid early inducible 1; TIGIT: T cell immunoglobulin and immunoreceptor tyrosine-based activation motif domain; TIM-3: T cell immunoglobulin domain and mucin domain 3; ULBP: UL16 binding proteins.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**